Serum Institute of India (SII) to conduct phase II and III human trial for the COVID-19 vaccine developed by the University of Oxford.
The permission was given on Sunday after an evaluation based on the recommendations of the Subject Expert Committee on COVID-19, a health ministry official told."The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official told the news agency PTI.